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Abstract
Background: It is important to determine the best drug-eluting stent (DES) for acute myocardial 
infarction (AMI) in patients with renal impairment. In this studythe outcomes of everolimus-eluting 
stents (EESs), zotarolimus-eluting stents (ZESs) and biolimus-eluting stents (BESs) were evaluated.
Methods: From the Korea Acute Myocardial Infarction-National Institutes of Health registry, a total 
of 1,470 AMI patients with renal impairment undergoing percutaneous coronary intervention (PCI) 
were enrolled (816 with EES, 345 with ZES, and 309 with BES). Renal impairment was defined as 
creatinine clearance < 60 mL/min/1.73 m2 estimated by the Cockcroft-Gault method. Major adverse 
cardiac and cerebrovascular events were determined as the composite of all-cause death, non-fatal myo-
cardial infarction (MI), cerebrovascular accident, any revascularization, rehospitalization and stent 
thrombosis. All clinical outcomes were analyzed.
Results: The baseline characteristics of the patients revealed no significant difference between the three 
groups, except for Killip classification > 2, beta-blockers, lesion type, vascular approach, staged PCI, left 
main coronary artery (LMCA) complex lesions, LMCA PCI, and the number and length of implanted 
stents. In the Kaplan-Meier analysis, similar clinical outcomes were derived from the unadjusted data 
between the three DES groups. However, after the inverse probability of treatment weighting, a statisti-
cally significant difference was found in non-fatal MI, which implied a higher incidence of non-fatal 
MI in the ZES group than in the other two DES groups.
Conclusions: In AMI patients with renal impairment, there was no significant difference between 
the three stent groups in terms of long-term clinical outcomes, except for non-fatal MI. (Cardiol J) 
Key words: myocardial infarction, renal insufficiency, drug-eluting stents, zotarolimus, 
everolimus, biolimus
Introduction
The incidence of acute coronary syndrome 
(ACS) with concomitant acute myocardial infarc-
tion (AMI), is gradually rising, leading to serious 
socioeconomic problems. Risk factors for coronary 
artery disease (CAD) such as diabetes, hyperten-
sion, and chronic kidney disease (CKD) are simi-
larly increasing. Among these risk factors, CKD 
is an independent risk factor for cardiovascular 
disease [1, 2]. In patients with end-stage kidney 
disease (ESKD), the incidence of cardiovascular 
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Acute myocardial infarction, a medical emer-
gency, is a type of ACS that requires rapid re-
vascularization. The advent of coronary stents, 
utilized for the treatment of coronary stenosis, has 
contributed to a decrease in both, restenosis and 
the likelihood of emergency coronary artery bypass 
grafting (CABG) [5, 6]. After 2002, the emer-
gence of drug-eluting stents (DESs), including 
the sirolimus-eluting stents (SESs) and paclitaxel-
eluting stents significantly reduced the incidence 
of restenosis and the need for repeat revasculariza-
tion compared with balloon angioplasty. The use of 
first-generation DES (1G-DES) has reduced the rate 
of target lesion revascularization (TLR) and CABG 
as a treatment option after stent implantation [7, 8]. 
However, there is an increasing concern about stent 
thrombosis, one of the most catastrophic phenom-
ena of percutaneous coronary intervention (PCI), 
which manifests as ST-segment elevation myo-
cardial infarction (STEMI) and/or sudden cardiac 
arrest requiring repeat revascularization [9]. Newer 
generation durable polymer-coated DESs using zo-
tarolimus or everolimus, called second-generation 
drug-eluting stents (2G-DESs), were developed 
to ameliorate polymer biocompatibility, leading to 
a significant reduction in in-stent restenosis, stent 
thrombosis, the duration of dual antiplatelet therapy 
(DAPT), and bleeding complications [10, 11]. In ad-
dition, biolimus-eluting stents (BESs), which use 
a biodegradable polymer, have been developed to 
treat long-term vascular complications related to 
durable polymers. Studies have shown that BES 
reduce late stent thrombosis compared with 1G-
DES [12]. In addition, it exhibited similar safety and 
efficacy characteristics compared with those of other 
2G-DESs [13, 14].
It has been established that cardiovascular 
disease is a leading cause of morbidity and mortal-
ity among CKD patients. CKD progresses through 
supply-demand mismatch, ischemic precondition-
ing, collateralization of blood vessels, and a high 
prevalence of left ventricular hypertrophy, leading 
to the development of CAD [2, 15].
In this study, the focus was on the differ-
ences in clinical outcomes between DESs in AMI 
patients. There is a paucity of clinical data on the 
difference in the outcomes between the three 
stent groups (zotarolimus-eluting stents [ZESs], 
everolimus-eluting stents [EESs], and BESs) in 
patients with AMI and renal impairment (AMI-RI). 
This clinical study aimed to elucidate the clinical 
differences between these three types of stents in 




The study population was extracted from 
the Korea Acute Myocardial Infarction Regis-
try-National Institutes of Health (KAMIR-NIH), 
a nationwide, multicenter, online observational 
cohort study. The KAMIR-NIH consecutively 
enrolled AMI patients at 20 major cardiovascular 
institutes between 2011 and 2015. Among 13,104 
AMI patients, a total of 4,692 AMI-RI patients 
were initially screened. The exclusion criteria 
included patients who: (a) had a prior myocardial 
infarction (MI); (b) died during index hospitaliza-
tion; (c) underwent no PCI or unsuccessful and/ 
/or partial revascularization during the index PCI; 
(d) underwent PCI without stent implantation or 
with stents other than the EES, ZES, or BES; (e) un- 
derwent CABG as a revascularization strategy; 
(f) underwent thrombolysis; and (g) received over-
lap implantations of two or three types of EES, 
ZES, or BES. After excluding 3,222 patients, a total 
of 1,470 patients were included in the study. These 
patients were classified into three groups as fol-
lows: (a) AMI-RI patients undergoing PCI with 
EES implantation (n = 816), (b) AMI-RI patients 
undergoing PCI with ZES implantation (n = 345), 
and (c) AMI-RI patients undergoing PCI with BES 
implantation (n = 309) (Fig. 1). Follow-up data of 
these patients were obtained mainly through regu-
larly scheduled outpatient visits. The present study 
was conducted according to the ethical principles 
of the Declaration of Helsinki, the best-known 
policy statement of the World Medical Associa-
tion, which was revised in 2013 [16]. Similarly, the 
study protocol of the KAMIR-NIH registry was also 
approved by the ethics committee of each partici-
pating center [17]. Written informed consent was 
secured from all participants.
Definition and clinical endpoints
Kidney function was determined by the cre-
atinine clearance (CrCl) calculated using the 
Cockcroft-Gault formula [18], and it was based 
on the serum creatinine level upon admission. In 
this study, renal impairment was determined as 
CrCl < 60 mL/min/1.73 m2 based on the serum 
creatinine level at the time of admission. 
Acute myocardial infarction was defined ac-
cording to current guidelines [19, 20], which include 
the typical rise and/or fall of biochemical markers of 
myocardial necrosis with at least one of the follow-
ing: (a) clinical symptoms indicative of myocardial 
ischemia, (b) development of pathological Q-waves 
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in the 12-lead electrocardiogram (ECG) results, 
(c) ECG changes indicative of ischemia (elevation 
or depression of the ST-segment), and (d) imaging 
modalities suggesting MI (i.e., new loss of viable 
myocardium or new-onset regional wall motion 
abnormality). STEMI was defined as AMI with 
new-onset ST-segment elevation of at least 1 mm 
(0.1 mV) in 2 or more contiguous leads, or new-onset 
left bundle branch block observed on ECG [21]. 
To quantitatively evaluate the left ventricle, left 
ventricular ejection fraction (LVEF) was examined 
using 2-dimensional echocardiography. The Killip 
classification, introduced in 1967, is defined as fol-
lows: Killip class I, no chronic heart failure; Killip 
class II, third heart sound and rales; Killip class III, 
overt pulmonary edema; and Killip class IV, 
cardiogenic shock [22]. Significant stenosis of the 
left main coronary artery (LMCA) was defined as 
an — at least — 50% reduction in the intralumi-
nal diameter of the LMCA. Unprotected left main 
disease was defined as the presence of significant 
stenosis in the LMCA with no patent bypass graft 
to the left anterior descending coronary artery or 
left circumflex coronary artery. LMCA complex 
lesions were defined as the presence of significant 
stenosis in the LMCA with the presence of added 
epicardial coronary artery stenosis. Significant 
stenosis of other epicardial coronary arteries was 
defined as a reduction of at least 70% in the intra-
luminal diameter of the epicardial coronary artery. 
The degree of coronary flow was quantitatively 
classified according to the Thrombolysis In Myo-
cardial Infarction (TIMI) flow grade.
Clinical follow-up was performed after the 
commencement of the study. The primary endpoint 
was major adverse cardiac and cerebrovascular 
events (MACCE), defined as the composite of 
all-cause death (cardiac and non-cardiac death), 
non-fatal MI, cerebrovascular accident (CVA), 
any revascularization using PCI or CABG, rehos-
pitalization, and stent thrombosis. The second-
ary endpoints were net adverse clinical events 
(NACE), all-cause mortality, non-fatal MI, any 
revascularization, CVA, rehospitalization, and stent 
thrombosis. NACE was defined as a composite of 
all-cause death, non-fatal MI, and any revasculari-
zation. Any revascularization was defined as any 
repeat PCI or CABG of any part of the epicardial 
coronary arteries overall. Rehospitalization was 
defined as post-index admission due to angina and/ 
/or heart failure.
Statistical analysis
All data analysis was performed using both 
STATA version 15.0 (StataCorp, College Station, 
Texas, United States of America) and SPSS ver-
The KAMIR-NIH Registry (November 2011–December 2015)
133,104 patients with acute myocardial infarction
4,692 patients with acute myocardial infarction and renal impairment
Study population (n = 1,470)
Exclusion criteria (n = 3,222):
— Prior myocardial infarction
— In-hospital death
— No PCI
— Unscuccessful and/or partial revascularization
— PCI without stent impalnation
— PCI with stents other than EES, ZES, and BES
— CABG
— Thrombolysis
— Stent of 2 or 3 types of EEC ZES, or BES
PCI with EES 
(n = 816)
PCI with ZES 
(n = 345)
PCI with BES 
(n = 309)
Figure 1. Flow chart for the selection of study participants; BES — biolimus-eluting stent; CABG — coronary artery 
bypass graft; EES — everolimus-eluting stent; KAMIR-NIH — Korea Acute Myocardial Infarction Registry-National 
Institutes of Health; PCI — percutaneous coronary intervention; ZES — zotarolimus-eluting stent.
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sion 25.0 (SPSS Inc., Armonk, New York, USA). 
Continuous variables were expressed as means 
± standard deviation and analyzed using the 
Student t-test and the analysis of variance test. 
Discrete (categorical) variables were represented 
as percentages with numbers and analyzed using 
the Pearson chi-squared test, the Fisher two-by- 
-two exact test, or linear by linear association. All 
results were considered statistically significant at 
p < 0.05.
To control for differences in baseline charac-
teristics and potential confounding factors, the pro-
pensity score weighting method, called the inverse 
probability of treatment weighting (IPTW), was 
applied [23]. The propensity score was constructed 
by a multiple logistic regression model using a total 
of 41 covariates. Participants with missing data in 
these covariates or whose follow-up period after 
hospital discharge was estimated as 0 days were 
excluded from IPTW adjustment.
Unadjusted and IPTW-adjusted survival analy-
ses were performed using  the Kaplan-Meier analy-
sis to determine the incidence of clinical outcomes, 
and log-rank (Mantel-Cox) tests were performed to 
evaluate differences among the treatment groups 
(i.e., EES, ZES, and BES groups).
Results
Baseline clinical and procedural  
characteristics
Baseline clinical characteristics are sum-
marized in Table 1. Before IPTW adjustment, 
a significant baseline difference was observed 
between the three groups in terms of the Killip 
classification at admission. Although the proportion 
of Killip classification > 2 in the ZES group was 
similar to that in the EES group, the BES group 
had a lower Killip classification than the other two 
groups. For discharge medications, there was a sig-
nificant difference in the use of beta-blockers. The 
BES group received a relatively low prescription 
of this medication compared with the EES group. 
Although the EES group had a higher proportion 
of patients with DAPT ≥ 12 months than the ZES 
group, the net difference was similar between the 
three groups.
In coronary angiography and procedural char-
acteristics (Table 2), some differences were ob-
served between the three groups. The BES group 
had a relatively lower incidence of pre-procedural 
TIMI flow grade 0–I and stent number ≥ 3. The 
incidence of thrombus aspiration was higher in the 
ZES group than in the EES group. The incidence 
of RCA PCI was higher in the ZES group than in 
the other two groups. The ZES group had a higher 
proportion of STEMI patients compared to the EES 
group. Nonetheless, the net difference between 
the three groups was similar for these variables. 
Meanwhile, the overall difference was found in 
terms of the American Heart Association and the 
American College of Cardiology lesion type, vascu-
lar approach, staged PCI, LMCA complex lesions, 
LMCA PCI, stent number, total stent length, and 
total stent length > 60 mm.
After IPTW adjustment, baseline clinical and 
procedural characteristics were balanced between 
the three DES groups (Suppl. Tables 1, 2).
Long-term follow-up clinical outcomes
After hospital discharge, follow-up was con-
ducted with a median delay of 1,088 days. Clinical 
outcomes of MACCE, NACE, all-cause mortality, 
non-fatal MI, any revascularization, CVA, rehospi-
talization and stent thrombosis were determined. 
Kaplan-Meier analysis was performed to describe 
the crude (unadjusted) and IPTW-adjusted survival 
curves, and the pair-wise log-rank test results for 
these comparisons are shown in Figures 2 and 3. 
Before IPTW adjustment, there were no significant 
differences in any clinical outcomes between the 
three DES groups. However, after IPTW, a signifi-
cant difference was found between these groups 
in terms of non-fatal MI. In the ZES group, the 
incidence of non-fatal MI was higher than in the 
other two groups. The number of patients at risk 
is shown in Table 3.
Discussion
This study demonstrates that except for non-
-fatal MI, there was no significant difference among 
the three stent groups concerning long-term 
MACCE, NACE, all-cause mortality, any revas-
cularization, CVA, rehospitalization and stent 
thrombosis. Regarding non-fatal MI, despite the 
significant difference not derived from unadjusted 
raw data analysis, IPTW-adjusted analysis showed 
that the ZES group had a higher incidence of non-
fatal MI than the other two groups (p = 0.005).
Chronic kidney disease is a major health is-
sue, with an increasing prevalence worldwide 
[24]; similarly, it is a debilitating medical condition, 
culminating in ESKD requiring dialysis or kidney 
transplantation, and is recognized as an independent 
cardiovascular risk factor [2, 25]. Among patients 
with renal impairment, cardiovascular events such as 
CAD, are the main cause of mortality [25, 26]. CKD 
4 www.cardiologyjournal.org
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Figure 2. Kaplan-Meier survival analyses of long-term follow-up clinical outcomes (MACCE, NACE, and all-cause mor-
tality, non-fatal MI, any revascularization, CVA, rehospitalization, and stent thrombosis), stratified according to stent 
types (before inverse probability of treatment weighting); CVA — cerebrovascular accident; MACCE — major adverse 
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Figure 3. Kaplan-Meier survival analyses of long-term follow-up clinical outcomes (MACCE, NACE, and all-cause mor-
tality, non-fatal MI, any revascularization, CVA, rehospitalization, and stent thrombosis), stratified according to stent 
types (after inverse probability of treatment weighting); CVA — cerebrovascular accident; MACCE — major adverse 
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patients tend to have a higher risk of experiencing 
cardiovascular events than patients with normal 
kidney function [27, 28]. Furthermore, the 2-year 
mortality rate after AMI is approximately 50% in 
ESKD patients, which is much higher than the mor-
tality rate after AMI in the general population [29]. 
Some large-scale studies demonstrated that reduced 
kidney function was independently associated with an 
increased risk of mortality and cardiovascular events 
in patients with reduced LVEF [30, 31]. A similar 
trend was observed between kidney function and 
cardiovascular events in an AMI setting [25]. 
Although the mechanism underlying the de-
velopment of cardiovascular disorders by renal 
impairment is still not well understood, it may 
be explained by several factors related to renal 
impairment. The progression of renal impairment 
is closely related to systemic inflammation and 
oxidative stress, which are responsible for the 
clinical manifestations of numerous complications, 
including atherosclerosis, vascular calcification 
(calciphylaxis), anemia, heart failure, and derange-
ments in calcium-phosphate homeostasis (mineral 
and bone disorders) [32–34]. Additionally, CKD is 
associated with an increased risk of thrombosis 
[35]. In CKD patients, clinically relevant throm-
bosis often presents as venous thromboembolism, 
vascular access-associated thrombosis, and right 
atrial thrombosis [35]. Similarly, thrombosis may 
occur within arteries, presenting as CAD, CVA, 
or peripheral artery disease [36]. These factors 
are directly and/or indirectly associated with car-
diovascular disorders and may contribute to the 
development of cardiovascular events in patients 
with renal impairment. Meanwhile, the prevalence 
of coronary risk factors tends to be high in CKD 
patients [37, 38]. In the present study, the propor-
tion of patients with hypertension and diabetes 
mellitus increased with the worsening of the CrCl 
(Suppl. Table 3). Because these coronary risk 
factors, including hypertension and diabetes mel-
litus, are equally recognized as predictors of renal 
impairment, they may worsen kidney function, 
subsequently increasing the influence of such risk 
factors [25]. This synergistic effect is also reflected 
in the present study, as lower CrCl caused lower 
LVEF with increasing incidence of the two afore-
mentioned coronary risk factors (Suppl. Table 3). 
Several clinical studies have compared the clini-
cal outcomes of implanted coronary stents in patients 
with AMI who underwent PCI. DES implantation 
showed better clinical outcomes than the bare-metal 
stent in reducing MI and mortality after PCI [39, 40]. 
Some studies compared 2G-DES and BES in AMI 
patients. Kim et al. [41] compared the 2-year clini-
cal outcomes of 2G-DES with those of BES in AMI 
patients with dyslipidemia after PCI and found similar 
results. Choe et al. [42] reported that BES shows 
clinical outcomes similar to those of new-generation 
DES. An article about the network meta-analysis of 
the efficacy and safety of coronary stents in patients 
with STEMI showed comparable results regarding 
the risk of primary outcomes between the DES 
groups, including the ZES, EES, and BES groups [40]. 
Similarly, there are published papers compar-
ing stents in patients with AMI and renal impair-
ment. Hachinohe et al. [43] reported that ZES 
results in a higher frequency of major adverse 
cardiovascular events (MACE) due to the increased 
TLR rate compared with SES in AMI patients with 
concomitant CKD. Ahmed et al. [44] compared 
the ZES and EES in STEMI patients with CKD 
undergoing PCI, and their results showed similari-
ties with the risk of 12-month MACE and death in 
patients with STEMI and CKD undergoing PCI.
Unlike these studies comparing two stent 
groups among AMI-RI patients, the current study 
is the first to compare clinical outcomes between 
three DES groups in selected AMI-RI patients un-
dergoing PCI. This study highlights that the use of 
ZES is associated with the occurrence of non-fatal 
MI compared with the use of the other two DESs. 
In addition, clinical findings herein, were based 
on a longer follow-up period than in previously 
published articles that were mentioned earlier. 
Nonetheless, it is still unclear why this signifi-
cant result was derived regarding non-fatal MI. It 
was mainly driven by the difference between ZES 
and EES groups, or between ZES and EES groups. 
In a comparative study evaluating 5-year efficacy 
of both EES and Resolute ZES in PCI-treated 
ACS patients, Resolute ZES demonstrated worse 
long-term outcomes than EES [45]. The authors of 
this study emphasized that the clinical differences 
between the two stent types were mainly driven 
by the polymer characteristics, not by the anti-
proliferative agents. Because the fluoropolymer, 
a highly fluorinated bilayer copolymer, coated with 
EES platform has high biocompatibility, reduces 
platelet adhesion and thrombus formation, these 
characteristics seems to influence better long-
-term outcomes in EES compared to Resolute 
ZES. Meanwhile, unlike both ZES and EES, which 
have durable polymers, BES has biodegradable 
polymers. In the BIOSTEMI trial, biodegradable 
polymer DES was statistically superior to durable 
polymer DES among STEMI patients [46]. Simi-
larly, in the present study, BES showed relatively 
www.cardiologyjournal.org 9
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good clinical outcomes (MACCE, NACE, cardiac 
death, non-fatal MI, any revascularization, and re-
hospitalization), although many of them were not 
statistically insignificant. Additionally, the statisti-
cal process should be considered in interpreting 
these results. In total, 110 patients (patients with 
a follow-up of 0 days or patients with any missing 
value in 41 covariates) were excluded from the 
IPTW-adjusted analysis. Thus, selection bias may 
have occurred in this process, causing disparities 
in non-fatal MI outcomes before and after IPTW 
(p-value of 0.091 before IPTW, and 0.005 after IPTW).
Limitations of the study
There are several limitations to be considered 
when interpreting the results of this study. First, 
the contributing institutions in the KAMIR-NIH 
registry tended to be tertiary centers with a higher 
volume of patients than average medical institutes. 
Thus, the mortality rates and treatment practice 
patterns could not be generalized to all medical 
institutions treating STEMI patients. Second, 
the information concerning hemodialysis in the 
KAMIR-NIH registry was not considered, making 
it impossible to separate hemodialysis patients 
from non-hemodialysis patients. Third, detailed 
stent information such as stent material, stent 
linker type, strut thickness, and polymer coating, 
to account for the heterogeneity of each DES, were 
not included in the analysis. Moreover, the KAMIR-
-NIH registry does not include several important 
angiographic profiles and lesion characteristics 
such as the presence of bifurcation lesion, chronic 
total occlusion, overlapping stents, use of shock-
wave intravascular lithotripsy and the use of rota-
tional atherectomy. Fourth, considering the timing 
of data collection, older types of DESs, which are 
no longer used in routine clinical practice, could 
undoubtedly also be included in the analysis. Fifth, 
this study was based on an observational registry; 
however, it was a non-randomized study. Hence, 
although statistical adjustment using the propen-
sity score weighting method was conducted to 
overcome this limitation, a large-scale multicenter 
randomized controlled trial is needed in the future.
Conclusions
In summary, there were no differences in the 
long-term clinical outcomes between the ZES, 
EES, and BES groups in AMI-RI patients undergo-
ing PCI, except for non-fatal MI. Unlike EES, ZES 
may be a predictor of non-fatal MI.
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